Compare KMDA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KMDA | CTNM |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.3M | 550.7M |
| IPO Year | 2013 | 2024 |
| Metric | KMDA | CTNM |
|---|---|---|
| Price | $8.15 | $9.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $13.75 | ★ $21.43 |
| AVG Volume (30 Days) | 103.5K | ★ 506.3K |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | ★ 6.86% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | $13.63 | N/A |
| P/E Ratio | $24.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.60 | $6.73 |
| 52 Week High | $9.35 | $17.79 |
| Indicator | KMDA | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 46.04 |
| Support Level | $7.99 | $8.59 |
| Resistance Level | $8.62 | $13.72 |
| Average True Range (ATR) | 0.25 | 0.74 |
| MACD | 0.09 | 0.19 |
| Stochastic Oscillator | 88.61 | 41.47 |
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.